Cost-effectiveness of nursing interventions for diabetic foot ulcer management: systematic review
Abstract
Introduction Nursing interventions used for the treatment of diabetic foot ulcers include traditional and advanced healing techniques. Often their choice depends on the nurse's personal judgment, rather than recognition of cost-effectiveness. The objective of this study is to identify the most cost-effective nursing interventions for the management of patients with diabetic foot ulcers. Methodology. A systematic review was conducted at Pubmed, Cochrane and the Virtual Health Library. Randomized and non-randomized studies of any nursing intervention used for diabetic foot ulcer management with reported cost-effectiveness were included. The selection of eligible articles was made by two independent reviewers. The risk of bias was assessed using the following guidelines: Critical Appraisal Skills Programme. Results. Six of the eight included articles were classified at high risk of bias. The two interventions in which a better cost-effectiveness ratio was evidenced compared to the control group were the use of Beta-Glucan gel (compared to placebo) and negative pressure wound therapy (compared to advanced wet wound therapy). Discussion. National and international guidelines for the nursing management of diabetic foot ulcers propose at least 15 different interventions. However, the limited availability of high-quality cost-effectiveness studies makes selection difficult and generates greater variability in nursing practices. Conclusion. Cost-effectiveness studies with direct comparisons of nursing interventions for diabetic foot ulcer management are needed.
References
Referencias
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1211-1259. DOI: http://doi.org/10.1016/S0140-6736(17)32154-2
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018. doi: https://doi.org/10.1016/S0140-6736(18)32203-7
Institute for Health Metrics and Evaluation. Global Health Data Exchange [Internet]. GBD results tool; 2020 [citado 10 de septiembre de 2020]. Recuperado a partir de: http://ghdx.healthdata.org/gbd-results-tool
Vargas-Uricoechea H and Casas-Figueroa LÁ. An Epidemiologic Analysis of Diabetes in Colombia. Annals of Global Health. 2016; 81(6), pp.742-753. doi: https://doi.org/10.1016/j.aogh.2015.11.001
Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215-22. doi: https://doi.org/10.1016/S0140-6736(10)60484-9
Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014; 383(9933):1973-80. doi: https://doi.org/10.1016/S0140-6736(14)60040-4
Seferovic JP, Bentley-Lewis R, Claggett B, Diaz R, Gerstein HC, Køber LV, et al. Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. J Diabetes Res. 2018. 1631263. doi: https://doi.org/10.1155/2018/1631263
Saed L, Deihim Z, Naghshbandi MK, Rajabnia M, Naleini SN. Cardiovascular events in patients with over 10 years history of type 2 diabetes mellitus. Diabetes Metab Syndr. 2019; 13(1):68-72. doi: https://doi.org/10.1016/j.dsx.2018.08.026
Kastarinen M., Juutilainen A., Kastarinen H., Salomaa V., Karhapaa P., Tuomilehto J., et al. Risk factors for end-stage renal disease in a community based population: 26-year follow-up of 25,821 men and women in eastern Finland. J. Intern. Med. 2010; 267(6): 612-620. doi: https://doi.org/10.1111/j.1365-2796.2009.02197.x
Shen Y, Cai R, Sun J, Dong X, Huang R, Tian S, Wang S. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine. 2017; 55(1):66-76. doi: https://doi.org/10.1007/s12020-016-1014-6
Vrsalovic M, Vucur K, Vrsalovic Presecki A, Fabijanic D, Milosevic M. Impact of diabetes on mortality in peripheral artery disease: a meta-analysis. Clin Cardiol. 2017; 40(5):287-291. doi: https://doi.org/10.1002/clc.22657
Blanes JI., Lluch I., Morillas C., Nogueira JM., Hernández A. Capítulo 3 Etiopatogenia del pie diabético. En: J. Marinel.lo Roura, Coordinador. Tratado del pie diabético. España: Jarpyo Editores; 2002. p33- 41.
University of Salford Manchester. Limbless statistics. United Kingdom. 2005. Citado 3 nov 2018. Recuperado a partir de: http://www.limbless-statistics.org/
Ziegler-Graham K, MacKenzie EJ, Ephraim PL, Travison TG, Brookmeyer R. Estimating the prevalence of limb loss in the United States: 2005 to 2050. Arch Phys Med Rehab 2008;89(3):422-429. https://doi.org/10.1016/j.apmr.2007.11.005
Font-Jiménez I, Llaurado-Serra M, Roig-Garcia M, De Los Mozos-Perez B, Acebedo-Urdiales S. Retrospective study of the evolution of the incidence of non-traumatic lower-extremity amputations (2007-2013) and risk factors of reamputation. Prim Care Diabetes. 2016;10(6):434-441. doi: https://doi.org/10.1016/j.pcd.2016.04.001
Vaidya V, Gangan N, Sheehan J. Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):487-497. doi: https://doi.org/10.1586/14737167.2015.1024661
Kerr M, Barron E, Chadwick P, et al. The cost of diabetic foot ulcers and amputations to the National Health Service in England. Diabet Med. 2019;36(8):995-1002. doi: https://doi.org/10.1111/dme.13973
International Diabetes Federation. Atlas de la Diabetes. Séptima Edición. 2015. Citado 3 nov 2018. Recuperado a partir de: https://www.fundaciondiabetes.org/upload/publicaciones_ficheros/95/IDF_Atlas_2015_SP_WEB_oct2016.pdf
Organización Mundial de la Salud. Informe mundial sobre la diabetes. 2016. Citado 3 nov 2018. Recuperado a partir de: https://www.who.int/diabetes/global-report/es/)
Barcelo A, Arredondo A, Gordillo-Tobar A, Segovia J, Qiang A. The cost of diabetes in Latin America and the Caribbean in 2015: Evidence for decision and policy makers. J Glob Health. 2017;7(2):020410. doi: https://doi.org/10.7189/jogh.07.020410
Hicks CW, Selvarajah S, Mathioudakis N, et al. Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. J Vasc Surg. 2014;60(5):1247-1254.e2. doi: https://doi.org/10.1016/j.jvs.2014.05.009
González J, Walker J, Einarson T. Cost-of-illness study of type 2 diabetes mellitus in Colombia. Rev Panam Salud Publica. 2009;26(1):55-63. Recuperado a partir de: https://www.scielosp.org/article/rpsp/2009.v26n1/55-63/ doi: https://doi.org/10.1590/S1020-49892009000700009
Méndez FA, Rivero WM. Costos médicos directos de complicación en el tratamiento en pacientes con diabetes mellitus en Colombia 2016 [tesis en Internet]. [Bogotá]: Universidad de Ciencias aplicadas y ambientales; 2016. [Citado 3 nov 2018. Recuperado a partir de: https://repository.udca.edu.co/bitstream/11158/859/1/TESIS%20PARA%20IMPRESION%20FINAL.pdf
Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers [published correction appears in Diabetes Care. 2014 Sep;37(9):2660]. Diabetes Care. 2014;37(3):651-658. doi: https://doi.org/10.2337/dc13-2176
Torra J. Economía de la Salud del Pie Diabético: Una revisión integrativa. En: 2ª Cumbre de las Americas del Pie Diabético; 2017 Oct 12. Ciudad de México. Citado 10 sep 2020. Recuperado a partir de: https://www.researchgate.net/publication/321151845_Economia_de_la_Salud_del_Pie_Diabetico_Una_revision_integrativa-_Diabetic_Foot_Health_Economics_An_integrative_review_Presentation_in_Spanish
Wang C, Guo M, Zhang N, Wang G. Effectiveness of honey dressing in the treatment of diabetic foot ulcers: A systematic review and meta-analysis. Complement Ther Clin Pract. 2019;34:123-131. doi: https://doi.org/10.1016/j.ctcp.2018.09.004
Everett E, Mathioudakis N. Update on management of diabetic foot ulcers. Ann N Y Acad Sci. 2018;1411(1):153-165. doi: https://doi.org/10.1111/nyas.13569
Martí-Carvajal AJ, Gluud C, Nicola S, Simancas-Racines D, Reveiz L, Oliva P, Cedeño-Taborda J. Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev. 2015;(10):CD008548. doi: https://doi.org/10.1002/14651858.CD008548.pub2
Saco M, Howe N, Nathoo R, Cherpelis B. Comparing the efficacies of alginate, foam, hydrocolloid, hydrofiber, and hydrogel dressings in the management of diabetic foot ulcers and venous leg ulcers: a systematic review and meta-analysis examining how to dress for success. Dermatol Online J. 2016;22(8). pii: 13030/qt7ph5v17z. Recuperado a partir de: https://www.researchgate.net/publication/307566354_Comparing_the_efficacies_of_alginate_foam_hydrocolloid_hydrofiber_and_hydrogel_dressings_in_the_management_of_diabetic_foot_ulcers_and_venous_leg_ulcers_A_systematic_review_and_meta-analysis_examining
O'Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assess. 2000; 4(21):1-237. Recuperado a partir de: https://www.journalslibrary.nihr.ac.uk/hta/hta4210 DOI: https://doi.org/10.3310/hta4210
Snyder RJ, Hanft JR. Diabetic foot ulcers--effects on QOL, costs, and mortality and the role of standard wound care and advanced-care therapies. Ostomy Wound Manage. 2009 Nov 1;55(11):28-38. Recuperado a partir de: https://www.semanticscholar.org/paper/Diabetic-Foot-Ulcers%3A-The-Importance-of-Patient-and-Jagadish-McNally/69658d1af9aa37c72b38cc661ad7bc2c2d9d6b50
Cutting KF. The cost-effectiveness of a novel soluble beta-glucan gel. J Wound Care. 2017;26(5):228-234. doi: https://doi.org/10.12968/jowc.2017.26.5.228
Driver VR, Blume PA. Evaluation of wound care and health-care use costs in patients with diabetic foot ulcers treated with negative pressure wound therapy versus advanced moist wound therapy. J Am Podiatr Med Assoc. 2014; 104(2):147-53. doi: https://doi.org/10.7547/0003-0538-104.2.147
Waycaster CR, Gilligan AM, Motley TA. Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer Healing. J Am Podiatr Med Assoc. 2016;106(4):273-82. doi: https://doi.org/10.7547/15-004
Zelen CM, Orgill DP, Serena T, Galiano R, Carter MJ, DiDomenico LA, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safetyand cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Int Wound J. 2017;14(2):307-315. doi: https://doi.org/10.1111/iwj.12600
Gilligan AM, Waycaster CR, Landsman AL. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products. J Wound Care. 2015;24(3):149-56. doi: https://doi.org/10.12968/jowc.2015.24.3.149
Gilligan AM, Waycaster CR, Motley TA. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers. Wound Repair Regen. 2015;23(3):353-60. doi: https://doi.org/10.1111/wrr.12285
Rice JB, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Skornicki M, et al. Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers. J Med Econ. 2015; 18(8):586-95. doi: https://doi.org/10.3111/13696998.2015.1031793
Wilasrusmee C, Marjareonrungrung M, Eamkong S, Attia J, Poprom N, Jirasisrithum S, et al. Maggot therapy for chronic ulcer: a retrospective cohort and a meta-analysis. Asian J Surg. 2014;37(3):138-47. doi: https://doi.org/10.1016/j.asjsur.2013.09.005
Aalaa M, Malazy OT, Sanjari M, Peimani M, Mohajeri-Tehrani M. Nurses' role in diabetic foot prevention and care; a review. J Diabetes Metab Disord. 2012;11(1):24. Published 2012 Nov 21. doi: https://doi.org/10.1186/2251-6581-11-24
Registered Nurses' Association of Ontario. Valoración y manejo de las úlceras de pie diabético. En: Grispun D, Director. Guías de buenas prácticas clínicas. Canadá; 2013. p1- 162. Recuperado a partir de: https://rnao.ca/sites/rnao-ca/files/2015_-_BPG_Foot_16_01_2015_-_2nd_Edition.pdf
COLPEDIS. Grupo Colombiano de Pie Diabético. Guías Colombianas para la prevención, diagnóstico y tratamiento del pie diabético. Tercera edición. 2019; 1- 63. Recuperado a partir de: https://es.scribd.com/document/411231925/Guias-Colombianas-Para-La-Prevencion-Diagnostico-y-Tratamiento-Del-Pie-Diabetico-Un-Manejo-Integral-2019
Parker CN, Van Netten JJ, Parker TJ, et al. Differences between national and international guidelines for the management of diabetic foot disease. Diabetes Metab Res Rev. 2019;35(2):e3101. doi: https://doi.org/10.1002/dmrr.3101
Beuscher T. Guidelines for Diabetic Foot Care. A Template for the Care of All Feet. J Wound Ostomy Continence Nurs. 2019;46(3):241-245. Recuperado a partir de: https://nursing.ceconnection.com/ovidfiles/00152192-201905000-00014.pdf;jsessionid=D90236391B51E13CF4AA937282AC0F13 doi: https://doi.org/10.1097/WON.0000000000000532
Schaper NC, van Netten JJ, Apelqvist J, et al. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36 Suppl 1:e3266. doi: https://doi.org/10.1002/dmrr.3266
Asociación latinoamericana de diabetes. Guías ALAD sobre el Diagnóstico, Control y Tratamiento de la Diabetes Mellitus Tipo 2 con Medicina Basada en Evidencia Edición 2019. 2019. Revista de la ALAD. Recuperado a partir de: http://www.revistaalad.com/guias/5600AX191_guias_alad_2019.pdf
Downloads
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
